Forms

RYR1-Related Congenital Myopathies via RYR1 Gene Sequencing with CNV Detection

  • Summary and Pricing
  • Clinical Features and Genetics
  • Citations
  • Methods
  • Ordering/Specimens
Order Kits
TEST METHODS

Sequencing with CNV

Test Code Test Copy GenesPriceCPT Code Copy CPT Codes
11631 RYR1$890 81408,81479 Add to Order

New York State Approved Test

Pricing Comments

Our favored testing approach is exome based NextGen sequencing with CNV analysis. This will allow cost effective reflexing to PGxome or other exome based tests. However, if a lower cost sequencing option without CNV detection is desired, please see this link for Test Code, pricing, and turnaround time information. If the alternative option is selected, CNV detection may be ordered through Test #600.

Targeted Testing

For ordering sequencing of targeted known variants, please proceed to our Targeted Variants landing page.

Turnaround Time

The great majority of tests are completed within 26 days.

Clinical Sensitivity

In a study to address the prevalence of congenital myopathy in a U.S. pediatric population, Amburgey et al. (2011) found RYR1 to be the most common overall cause. Thirteen of 46 cases were found to have RYR1 mutations for an estimated prevalence of 1:90,000. Similarly, RYR1 was found to be responsible for 26 of 44 congenital myopathy cases in a European cohort (Maggi et al. 2013). Clinical sensitivity is reported to be in excess of 90% in cases of CCD (Wu et al. 2006), and RYR1 mutations have been shown to be one of the most common causes of CFTD (Clarke et al. 2010). In a clinically and histologically well defined cohort of multiminicore patients, three of five families were found to have RYR1 mutations (Jungbluth et al. 2005). Analytical sensitivity is high with Next-Generation sequencing or Sanger sequencing because most RYR1 causative mutations are detectable by these methods.

Clinical sensitivity for gross deletion/duplication testing is likely low because, to date, only one gross deletion has been reported (Monnier et al. 2008).

See More

See Less

Clinical Features

Congenital myopathy refers to a group of neuromuscular disorders that most often present in childhood and have characteristic histopathological features in skeletal muscle. Based on histopathology, the three main types of congenital myopathy are core myopathy, centronuclear myopathy, and nemaline rod myopathy. Pathological RYR1 gene variants are causative for core myopathy, centronuclear myopathy, and core/rod myopathy. Cores are areas of the muscle that abnormally lack oxidative and glycolytic enzymatic activity. These areas of clearing reflect an absence of mitochondria in the muscle. Cores are further classified as central cores, which run the length of the muscle cell, or minicores, which are wider than they are long. Nemaline rods are rod-shaped structures in the sarcoplasm that contain material from the degenerated Z-disk.

Central core disease (CCD) is a static or slowly progressive myopathy that demonstrates a wide range of clinical severity and age of onset, but uniform histopathology. In the newborn period, CCD results in a floppy infant with feeding difficulties, respiratory insufficiency, myopathic facies, and extraocular muscle weakness. Skeletal abnormalities include talipes equinovarus and congenital dislocation of the hips. Childhood-onset CCD presents with mild proximal weakness involving hip and axial muscles and delayed motor development. Skeletal findings such as scoliosis and equinovarus are other complications (Jungbluth et al. 2007). Cases of adult-onset CCD with generally milder clinical symptoms have been described (Duarte et al. 2011). One representative patient had normal arm and leg strength and normal muscle bulk, but was easily fatigued and had difficulty maintaining an upright posture (Jungbluth et al. 2009). Intrafamilial variability of disease severity and pathology is also known (Sewry et al. 2002). Imaging of muscle groups in CCD patients reveals a distinct pattern of involvement (Fischer et al. 2006). The most severely affected muscles are gluteus maximus, medial and anterior compartments of the thigh muscles, and soleus and lateral gastrocnemius muscles of the lower leg.

The other congenital myopathies associated with the RYR1 gene demonstrate a much broader spectrum of histopathology and diagnostic imaging patterns than does CCD (Wilmshurst et al. 2010; Klein et al. 2011; Mercuri, E. et al. 2010). Associated histopathological findings include multiminicores, centrally placed nuclei, and congenital fiber type disproportion.

RYR1-related minicore myopathy is also known as multiminicore myopathy with external ophthalmoplegia because involvement of extraocular muscles is a nearly universal finding (Jungbluth et al. 2000; Monnier et al. 2009). Clinical signs include severe neonatal hypotonia, respiratory problems, feeding difficulties, frequent respiratory infections, delayed motor development, scoliosis, kyphoscoliosis, contractures, and myopathic facies (Wilmshurst et al. 2010).

RYR1-related centronuclear myopathy is associated with infantile-onset proximal weakness, external ophthalmoplegia, and bulbar involvement, followed by progressive improvement of symptoms. Histopathological findings in muscle biopsied from young patients include internalized nuclei and type 1 fiber predominance. However, when biopsied later in life, two-thirds of patients in one study had central cores or minicores in their muscle (Wilmshurst et al. 2010).

Congenital fiber type disproportion is a genetically heterogeneous disorder defined as hypotrophy of type 1 fibers compared to type 2 fibers. Patients with RYR1-related CFTD exhibit generalized hypotonia, motor delays, recurrent respiratory infections, a weak cry, ptosis, ophthalmoplegia, facial weakness, scoliosis, and contractures (Clarke et al. 2010).

The clinically most severe cases of RYR1-related myopathy present with decreased fetal movement, hypotonia, poor feeding, respiratory involvement, arthrogryposis, and ophthalmoplegia (Bharucha-Goebel et al. 2013). Additional features include fractures or hip dislocation at birth. In the published cohort of patients, the severe neonatal onset cases with dominant acting RYR1 mutations had classic central cores on muscle biopsy, while those with recessive acting RYR1 mutations had notable histologic variability, including fibrosis, variation in fiber size, and nuclear internalization.RYR1 is also involved in exercise-induced rhabdomyolysis and myalgia (Dlamini et al. 2013). Many of the RYR1 mutations identified in these patients are documented to be associated with malignant hyperthermia risk. Patients that span a broad range of ages presenting with symptoms of exercise or heat-induced rhabdomyolisis and sometimes myalgia have been reported (Dlamini et al. 2013).

Malignant hyperthemia susceptibility is another well documented RYR1 disorder.

Genetics

The RYR1 gene encodes the skeletal muscle isoform of the ryanodine receptor. The RYR1 protein functions to regulate calcium release at the sarcoplasmic reticulum by serving as the calcium-induced, voltage-gated receptor, as well as the channel through which calcium flows. RYR1-related congenital myopathies are inherited as autosomal dominant and recessive disorders. Central core disease is typically dominant, with de novo and inherited mutations being well documented (Klein et al. 2012). The vast majority of CCD-causing mutations result in amino acid substitutions that lie in the C-terminus of the RYR1 protein (Zhou et al. 2007). The other RYR1-related congenital myopathies are most often inherited as autosomal recessive disorders, although exceptions exist. Recessive RYR1 myopathy cases are typically found to have one null allele and a second variant that results in an amino acid substitution or, as in the most severe neonatal forms, a second null allele (Bevilacqua et al. 2011; Monnier et al. 2008).

Testing Strategy

For this Next Generation Sequencing (NGS) test, sequencing is accomplished by capturing specific regions with an optimized solution-based hybridization kit, followed by massively parallel sequencing of the captured DNA fragments. Additional Sanger sequencing is performed for regions not captured or with insufficient number of sequence reads.

For Sanger sequencing, polymerase chain reaction (PCR) is used to amplify targeted regions. After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit. PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer. In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.

Copy number variants (CNVs) are also detected from NGS data. We utilize a CNV calling algorithm that compares mean read depth and distribution for each target in the test sample against multiple matched controls. Neighboring target read depth and distribution and zygosity of any variants within each target region are used to reinforce CNV calls. All CNVs are confirmed using another technology such as aCGH, MLPA, or PCR before they are reported.

This test provides full coverage of all coding exons of the RYR1 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.

Since this test is performed using exome capture probes, a reflex to any of our exome based tests is available (PGxome, PGxome Custom Panels).

Indications for Test

Patients that display clinical and histopathological features of the RYR1-related myopathies.

Gene

Official Gene Symbol OMIM ID
RYR1 180901
Inheritance Abbreviation
Autosomal Dominant AD
Autosomal Recessive AR
X-Linked XL
Mitochondrial MT

CONTACTS

Genetic Counselors
Geneticist
Citations
  • Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, Dowling JJ. 2011. Prevalence of congenital myopathies in a representative pediatric united states population. Annals of neurology 70: 662–665. PubMed ID: 22028225
  • Bevilacqua JA, Monnier N, Bitoun M, Eymard B, Ferreiro A, Monges S, Lubieniecki F, Taratuto AL, Laquerrière A, Claeys KG, Marty I, Fardeau M, et al. 2011. Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization. Neuropathol. Appl. Neurobiol. 37: 271–284. PubMed ID: 21062345
  • Bharucha-Goebel DX, Santi M, Medne L, Zukosky K, Dastgir J, Shieh PB, Winder T, Tennekoon G, Finkel RS, Dowling JJ, Monnier N, Bonnemann CG. 2013. Severe congenital RYR1-associated myopathy: The expanding clinicopathologic and genetic spectrum. Neurology 80: 1584–1589. PubMed ID: 23553484
  • Clarke NF, Waddell LB, Cooper ST, Perry M, Smith RLL, Kornberg AJ, Muntoni F, Lillis S, Straub V, Bushby K, Guglieri M, King MD, et al. 2010. Recessive mutations in RYR1 are a common cause of congenital fiber type disproportion. Human Mutation 31: E1544–E1550. PubMed ID: 20583297
  • Dlamini N, Voermans NC, Lillis S, Stewart K, Kamsteeg E-J, Drost G, Quinlivan R, Snoeck M, Norwood F, Radunovic A, Straub V, Roberts M, et al. 2013. Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disorders 23: 540–548. PubMed ID: 23628358
  • Duarte ST, Oliveira J, Santos R, Pereira P, Barroso C, Conceição I, Evangelista T. 2011. Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms. Muscle & nerve 44: 102–108. PubMed ID: 21674524
  • Fischer D, Herasse M, Ferreiro A, Barragan-Campos HM, Chiras J, Viollet L, Maugenre S, Leroy J-P, Monnier N, Lunardi J, Guicheney P, Fardeau M, et al. 2006. Muscle imaging in dominant core myopathies linked or unlinked to the ryanodine receptor 1 gene. Neurology 67: 2217–2220. PubMed ID: 17190947
  • Jungbluth H, Lillis S, Zhou H, Abbs S, Sewry C, Swash M, Muntoni F. 2009. Late-onset axial myopathy with cores due to a novel heterozygous dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscular Disorders 19: 344–347. PubMed ID: 19303294
  • Jungbluth H, Sewry C, Brown SC, Manzur AY, Mercuri E, Bushby K, Rowe P, Johnson MA, Hughes I, Kelsey A, Dubowitz V, Muntoni F. 2000. Minicore myopathy in children: a clinical and histopathological study of 19 cases. Neuromuscul. Disord. 10: 264–273. PubMed ID: 10838253
  • Jungbluth H, Zhou H, Hartley L, Halliger-Keller B, Messina S, Longman C, Brockington M, Robb SA, Straub V, Voit T, Swash M, Ferreiro A, et al. 2005. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene. Neurology 65: 1930–1935. PubMed ID: 16380615
  • Jungbluth H, Zhou H, Sewry CA, Robb S, Treves S, Bitoun M, Guicheney P, Buj-Bello A, Bönnemann C, Muntoni F. 2007. Centronuclear myopathy due to a de novo dominant mutation in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscul. Disord. 17: 338–345. PubMed ID: 17376685
  • Klein A, Jungbluth H, Clement E, Lillis S, Abbs S, Munot P, Pane M, Wraige E, Schara U, Straub V, Mercuri E, Muntoni F. 2011. Muscle magnetic resonance imaging in congenital myopathies due to ryanodine receptor type 1 gene mutations. Arch. Neurol. 68: 1171–1179. PubMed ID: 21911697
  • Klein A, Lillis S, Munteanu I, Scoto M, Zhou H, Quinlivan R, Straub V, Manzur AY, Roper H, Jeannet P-Y, Rakowicz W, Jones DH, et al. 2012. Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum. Mutat. 33: 981–988. PubMed ID: 22473935
  • Maggi L, Scoto M, Cirak S, Robb SA, Klein A, Lillis S, Cullup T, Feng L, Manzur AY, Sewry CA, Abbs S, Jungbluth H, et al. 2013. Congenital myopathies – Clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscular Disorders 23: 195–205. PubMed ID: 23394784
  • Mercuri E, Clements E, Offiah A, Pichiecchio A, Vasco G, Bianco F, Berardinelli A, Manzur A, Pane M, Messina S, Gualandi F, Ricci E, et al. 2010. Muscle magnetic resonance imaging involvement in muscular dystrophies with rigidity of the spine. Annals of Neurology 67: 201–208. PubMed ID: 20225280
  • Monnier N, Laquerrière A, Marret S, Goldenberg A, Marty I, Nivoche Y, Lunardi J. 2009. First genomic rearrangement of the RYR1 gene associated with an atypical presentation of lethal neonatal hypotonia. Neuromuscul. Disord. 19: 680–684. PubMed ID: 19734047
  • Monnier N, Marty I, Faure J, Castiglioni C, Desnuelle C, Sacconi S, Estournet B, Ferreiro A, Romero N, Laquerriere A, Lazaro L, Martin J-J, et al. 2008. Null mutations causing depletion of the type 1 ryanodine receptor (RYR1) are commonly associated with recessive structural congenital myopathies with cores. Hum. Mutat. 29: 670–678. PubMed ID: 18253926
  • Sewry CA, Müller C, Davis M, Dwyer JSM, Dove J, Evans G, Schröder R, Fürst D, Helliwell T, Laing N. 2002. The spectrum of pathology in central core disease. Neuromuscular Disorders 12: 930–938. PubMed ID: 12467748
  • Wilmshurst JM, Lillis S, Zhou H, Pillay K, Henderson H, Kress W, Müller CR, Ndondo A, Cloke V, Cullup T, Bertini E, Boennemann C, et al. 2010. RYR1 mutations are a common cause of congenital myopathies with central nuclei. Ann. Neurol. 68: 717–726. PubMed ID: 20839240
  • Wu S, Ibarra M CA, Malicdan MCV, Murayama K, Yasuko Ichihara Y, Kikuchi H, Nonaka I, Noguchi S, Hayashi YK, Nishino I. 2006. Central core disease is due to RYR1 mutations in more than 90% of patients. Brain 129: 1470–1480. PubMed ID: 16621918
  • Zhou H, Jungbluth H, Sewry CA, Feng L, Bertini E, Bushby K, Straub V, Roper H, Rose MR, Brockington M, Kinali M, Manzur A, et al. 2007. Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies. Brain 130: 2024–2036. PubMed ID: 17483490
Order Kits
TEST METHODS

Exome Sequencing with CNV Detection

Test Procedure

For the PGxome we use Next Generation Sequencing (NGS) technologies to cover the coding regions of targeted genes plus ~10 bases of non-coding DNA flanking each exon. As required, genomic DNA is extracted from patient specimens. Patient DNA corresponding to these regions is captured using Agilent Clinical Research Exome hybridization probes. Captured DNA is sequenced on the NovaSeq 6000 using 2x150 bp paired-end reads (Illumina, San Diego, CA, USA). The following quality control metrics are generally achieved: >97% of target bases are covered at >20x, and mean coverage of target bases >120x. Data analysis and interpretation is performed by the internally developed software Titanium-Exome. In brief, the output data from the NovaSeq 6000 is converted to fastqs by Illumina Bcl2Fastq, and mapped by BWA. Variant calls are made by the GATK Haplotype caller and annotated using in house software and SnpEff. Variants are filtered and annotated using VarSeq (www.goldenhelix.com).

For Sanger sequencing, polymerase chain reaction (PCR) is used to amplify targeted regions. After purification of the PCR products, cycle sequencing is carried out using the ABI Big Dye Terminator v.3.0 kit. PCR products are resolved by electrophoresis on an ABI 3730xl capillary sequencer. In nearly all cases, cycle sequencing is performed separately in both the forward and reverse directions.

Copy number variants (CNVs) are also detected from NGS data. We utilize a CNV calling algorithm that compares mean read depth and distribution for each target in the test sample against multiple matched controls. Neighboring target read depth and distribution and zygosity of any variants within each target region are used to reinforce CNV calls. All CNVs are confirmed using another technology such as aCGH, MLPA, or PCR before they are reported.

Analytical Validity

NextGen Sequencing: As of March 2016, 6.36 Mb of sequence (83 genes, 1557 exons) generated in our lab was compared between Sanger and NextGen methodologies. We detected no differences between the two methods. The comparison involved 6400 total sequence variants (differences from the reference sequences). Of these, 6144 were nucleotide substitutions and 256 were insertions or deletions. About 65% of the variants were heterozygous and 35% homozygous. The insertions and deletions ranged in length from 1 to over 100 nucleotides.

In silico validation of insertions and deletions in 20 replicates of 5 genes was also performed. The validation included insertions and deletions of lengths between 1 and 100 nucleotides. Insertions tested in silico: 2200 between 1 and 5 nucleotides, 625 between 6 and 10 nucleotides, 29 between 11 and 20 nucleotides, 25 between 21 and 49 nucleotides, and 23 at or greater than 50 nucleotides, with the largest at 98 nucleotides. All insertions were detected. Deletions tested in silico: 1813 between 1 and 5 nucleotides, 97 between 6 and 10 nucleotides, 32 between 11 and 20 nucleotides, 20 between 21 and 49 nucleotides, and 39 at or greater than 50 nucleotides, with the largest at 96 nucleotides. All deletions less than 50 nucleotides in length were detected, 13 greater than 50 nucleotides in length were missed. Our standard NextGen sequence variant calling algorithms are generally not capable of detecting insertions (duplications) or heterozygous deletions greater than 100 nucleotides. Large homozygous deletions appear to be detectable.

Copy Number Variant Analysis: The PGxome test detects most larger deletions and duplications including intragenic CNVs and large cytogenetic events; however aberrations in a small percentage of regions may not be accurately detected due to sequence paralogy (e.g., pseudogenes, segmental duplications), sequence properties, deletion/duplication size (e.g., 1-3 exons vs. 4 or more exons), and inadequate coverage. In general, sensitivity for single, double, or triple exon CNVs is ~70% and for CNVs of four exon size or larger is >95%, but may vary from gene-to-gene based on exon size, depth of coverage, and characteristics of the region.

Analytical Limitations

Interpretation of the test results is limited by the information that is currently available. Better interpretation should be possible in the future as more data and knowledge about human genetics and this specific disorder are accumulated.

When sequencing does not reveal any heterozygous differences from the reference sequence, we cannot be certain that we were able to detect both patient alleles.

For technical reasons, the PGxome test is not 100% sensitive. Some exons cannot be efficiently captured, and some genes cannot be accurately sequenced because of the presence of multiple copies in the genome. Therefore, a small fraction of sequence variants will not be detected.

We sequence coding exons for most given transcripts, plus ~10 bp of flanking non-coding DNA for each exon. Unless specifically indicated, test reports contain no information about other portions of the gene, such as regulatory domains, deep intronic regions, uncharacterized alternative exons, chromosomal rearrangements, repeat expansions, epigenetic effects, and mitochondrial genome variants.

In most cases, we are unable to determine the phase of sequence variants. In particular, when we find two likely causative mutations for recessive disorders, we cannot be certain that the mutations are on different alleles.

Our ability to detect minor sequence variants due to somatic mosaicism is limited. Sequence variants that are present in less than 50% of the patient's nucleated cells may not be detected.

Runs of mononucleotide repeats (eg (A)n or (T)n) with n >8 in the reference sequence are generally not analyzed because of strand slippage during amplification.

Unless otherwise indicated, DNA sequence data is obtained from a specific cell-type (usually leukocytes if taken from whole blood). Test reports contain no information about the DNA sequence in other cell-types.

We cannot be certain that the reference sequences are correct.

Balanced translocations or inversions are only rarely detected.

Certain types of sex chromosome aneuploidy may not be detected.  

Our ability to detect CNVs due to somatic mosaicism is limited.

We have confidence in our ability to track a specimen once it has been received by PreventionGenetics. However, we take no responsibility for any specimen labeling errors that occur before the sample arrives at PreventionGenetics.

A negative finding does not rule out a genetic diagnosis.

Genetic counseling to help to explain test results to the patients and to discuss reproductive options is recommended.

Order Kits

Ordering Options


myPrevent - Online Ordering
  • The test can be added to your online orders in the Summary and Pricing section.
  • Once the test has been added log in to myPrevent to fill out an online requisition form.
REQUISITION FORM
  • A completed requisition form must accompany all specimens.
  • Billing information along with specimen and shipping instructions are within the requisition form.
  • All testing must be ordered by a qualified healthcare provider.
SPECIMEN TYPES
WHOLE BLOOD

(Delivery accepted Monday - Saturday)

  • Collect 3 ml -5 ml (5 ml preferred) of whole blood in EDTA (purple top tube) or ACD (yellow top tube). For Test #500-DNA Banking only, collect 10 ml -20 ml of whole blood.
  • For small babies, we require a minimum of 1 ml of blood.
  • Only one blood tube is required for multiple tests.
  • Ship blood tubes at room temperature in an insulated container. Do not freeze blood.
  • During hot weather, include a frozen ice pack in the shipping container. Place a paper towel or other thin material between the ice pack and the blood tube.
  • In cold weather, include an unfrozen ice pack in the shipping container as insulation.
  • At room temperature, blood specimen is stable for up to 48 hours.
  • If refrigerated, blood specimen is stable for up to one week.
  • Label the tube with the patient name, date of birth and/or ID number.
DNA

(Delivery accepted Monday - Saturday)

  • Send in screw cap tube at least 5 µg -10 µg of purified DNA at a concentration of at least 20 µg/ml for NGS and Sanger tests and at least 5 µg of purified DNA at a concentration of at least 100 µg/ml for gene-centric aCGH, MLPA, and CMA tests, minimum 2 µg for limited specimens.
  • For requests requiring more than one test, send an additional 5 µg DNA per test ordered when possible.
  • DNA may be shipped at room temperature.
  • Label the tube with the composition of the solute, DNA concentration as well as the patient’s name, date of birth, and/or ID number.
  • We only accept genomic DNA for testing. We do NOT accept products of whole genome amplification reactions or other amplification reactions.
CELL CULTURE

(Delivery preferred Monday - Thursday)

  • PreventionGenetics should be notified in advance of arrival of a cell culture.
  • Culture and send at least two T25 flasks of confluent cells.
  • Some panels may require additional flasks (dependent on size of genes, amount of Sanger sequencing required, etc.). Multiple test requests may also require additional flasks. Please contact us for details.
  • Send specimens in insulated, shatterproof container overnight.
  • Cell cultures may be shipped at room temperature or refrigerated.
  • Label the flasks with the patient name, date of birth, and/or ID number.
  • We strongly recommend maintaining a local back-up culture. We do not culture cells.
loading Loading... ×

Copy Text to Clipboard
×